Another Win for Edwards'

Edwards Lifesciences (EW) Edwards Lifesciences Corp. develops, manufactures and markets products and technologies that are designed to treat advanced stage cardiovascular disease. In 2011, 64% of revenues were generated in markets outside the U.S.

[PostStockWidget stock_valuation="" pricetype="live" manual_date="Dec. 21, 2012, 2:04pm GMT" symbolcodes="'EW'" symbolprices="83" div_align="right"]

• We added Edwards to our holdings in May 2013 at $64.75 and at the time expected the company to reach $110. As it became clearer that our target was ahead of reality, we adjusted it to $78. Today with their court based win against Medtronic, the shares sailed past our target and we took profits at $83.58 and made 29%. We will now look for other opportunities.

• New Purple Chips Valuation Range: Low $65.00, high $78.00

• HIGH VALUATION IN EDWARDS LIFESCIENCES AT $USD 83.58 (EW $82.00) HALF POSITION

• This trade did not pay any dividends TOTAL RETURN: +28.8%